Thermo Fisher Scientific (TMO) Invested Capital (2009 - 2026)

Thermo Fisher Scientific has disclosed Invested Capital across 18 years of filings, most recently posting $94.9 billion for Q1 2026.

• Quarterly Invested Capital rose 13.84% year-over-year to $94.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.9 billion (up 13.84% YoY) and the FY2025 annual result came in at $92.6 billion, up 14.84% from the prior year.
• Invested Capital rose to $94.9 billion in Q1 2026, from $92.6 billion in the prior quarter.
• Over five years, Invested Capital peaked at $94.9 billion in Q1 2026 and troughed at $72.4 billion in Q3 2022.
• A 5-year average of $81.5 billion and a median of $80.9 billion in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 37.91% — and 2024, when it fell 1.02%.
• Tracing TMO's Invested Capital over 5 years: stood at $78.3 billion in 2022, then rose by 4.01% to $81.5 billion in 2023, then retreated by 1.02% to $80.6 billion in 2024, then increased by 14.84% to $92.6 billion in 2025, then advanced by 2.48% to $94.9 billion in 2026.
• Business Quant data shows TMO's Invested Capital at $94.9 billion in Q1 2026, $92.6 billion in Q4 2025, and $86.5 billion in Q3 2025.